Product Development In Brief; Novartis Elinogrel, Acorda Fampridine
Novartis targets elinogrel Phase III in 2010: After acquiring the anti-clotting compound elinogrel from Portola Pharmaceuticals in February, Novartis is planning to initiate Phase III trials of the drug in 2010, the Swiss drug maker says during first quarter sales and earnings update April 23. A large Phase III program will be required to evaluate safety, Global Head of Development, Pharma Trevor Mundel says. Elinogrel, which could have potential advantages over existing treatments like Bristol-Myers Squibb's Plavix (clopidogrel) as a reversible P2Y12 ADP receptor antagonist, currently is being studied in a 800-patient Phase II study. Novartis gained rights for the drug for $75 million upfront and $500 million in milestones (1"The Pink Sheet" DAILY, Feb. 12, 2009)
You may also be interested in...
FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug
Firm may need to refile NDA for mobility-boosting Fampridine-SR.
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011